United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.